Capmatinib

A phase II study (GEOMETRY [NCT02414139]) evaluated capmatinib (400 mg orally twice daily) in patients with MET exon 14-skipping variants or MET amplification. MET status was determined centrally. A total of 364 patients were enrolled. The primary end point was overall response.[56][Level of evidence C3]

A phase II study (GEOMETRY [NCT02414139]) evaluated capmatinib (400 mg orally twice daily) in patients with MET exon 14-skipping variants or MET amplification. MET status was determined centrally. A total of 364 patients were enrolled. The primary end point was overall response.[56][Level of evidence C3]

Of the 69 patients with MET exon 14-skipping variants who had received one or two prior lines of therapy, the overall response rate was 41% (95% CI, 29%–53%). The median DOR was 9.7 months (95% CI, 5.6–13.0).

A phase II study (GEOMETRY [NCT02414139]) evaluated capmatinib (400 mg orally twice daily) in patients with MET exon 14-skipping variants or MET amplification. MET status was determined centrally. A total of 364 patients were enrolled. The primary end point was overall response.[56][Level of evidence C3]

Of the 28 patients with MET exon 14-skipping variants who had not received any prior treatment, the overall response rate was 68% (95% CI, 48%–84%). The median DOR was 12.6 months (95% CI, 5.6–NE).

A phase II study (GEOMETRY [NCT02414139]) evaluated capmatinib (400 mg orally twice daily) in patients with MET exon 14-skipping variants or MET amplification. MET status was determined centrally. A total of 364 patients were enrolled. The primary end point was overall response.[56][Level of evidence C3]

Response rates in patients with MET amplification without exon 14-skipping variants did not meet the prespecified threshold for clinically relevant activity.

A phase II study (GEOMETRY [NCT02414139]) evaluated capmatinib (400 mg orally twice daily) in patients with MET exon 14-skipping variants or MET amplification. MET status was determined centrally. A total of 364 patients were enrolled. The primary end point was overall response.[56][Level of evidence C3]

Grade 3 to 4 adverse events occurred in 67% of patients. The most common events, regardless of causality, were peripheral edema, nausea, vomiting, and increased creatinine. Adverse events led to therapy discontinuation in 11% of patients.